2020
DOI: 10.1002/acn3.51206
|View full text |Cite
|
Sign up to set email alerts
|

Long‐term peripheral immune cell profiling reveals further targets of oral cladribine in MS

Abstract: Objectives: To expand the knowledge about the immunological consequences of cladribine (CLAD), a pulsed immune reconstitution therapy approved for active multiple sclerosis (MS), beyond the known short-term effects on peripheral immune cell subsets. Methods: In this study, we characterized depletion and restitution kinetics as well as cytokine profiles of peripheral immune cell subsets in 18 patients with MS following treatment with oral CLAD. The methods involved blood collection prior to CLAD and every three… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

10
48
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8

Relationship

4
4

Authors

Journals

citations
Cited by 46 publications
(59 citation statements)
references
References 31 publications
(58 reference statements)
10
48
0
1
Order By: Relevance
“…Cladribine is a synthetic purine nucleoside analogue that predominantly targets lymphocytes, disrupting DNA synthesis and repair and leading to cell death. In MS patients cladribine induces modest CD4 and CD8 T cell depletion and a more marked and persistent reduction in circulating B cells, mainly memory B cells, which could be the main mechanism underlying its efficacy ( 301 , 302 ). A preliminary study showing disappearance of CSF oligoclonal Ig bands in about half of MS patients 10 years after cladribine treatment suggests that cladribine also depletes B-cells within the CNS ( 300 ).…”
Section: Cd8 T Cell and B Cell Changes Induced By Ms Treatmentsmentioning
confidence: 99%
“…Cladribine is a synthetic purine nucleoside analogue that predominantly targets lymphocytes, disrupting DNA synthesis and repair and leading to cell death. In MS patients cladribine induces modest CD4 and CD8 T cell depletion and a more marked and persistent reduction in circulating B cells, mainly memory B cells, which could be the main mechanism underlying its efficacy ( 301 , 302 ). A preliminary study showing disappearance of CSF oligoclonal Ig bands in about half of MS patients 10 years after cladribine treatment suggests that cladribine also depletes B-cells within the CNS ( 300 ).…”
Section: Cd8 T Cell and B Cell Changes Induced By Ms Treatmentsmentioning
confidence: 99%
“…These observations were made for a total dose of cladribine of 3.5 mg/kg vs. 5.25 mg/kg. In addition, cladribine treatment led to changes in the absolute cell count, relative distribution of many lymphocyte subsets and lowering of TH17 subsets [ 32 ]. The relationship of these observations to clinical effects remains to be elucidated.…”
Section: Immunological Consequences Of Immune-depleting Therapies mentioning
confidence: 99%
“…Cladribine is a DMT that has a long-term efficacy due to its mode of action. It shows a selectivity towards proinflammatory immune cell subsets, resulting in transient depletion of memory B cell and TH17 cell populations, while leaving the innate immune system intact [5]. The modest depletion induced by cladribine in T and NK cells and a more marked depletion of B cells are seen most significantly between the first and third months [5].…”
Section: Discussionmentioning
confidence: 99%